Milestone Pharmaceuticals
MIST
28 hedge funds and large institutions have $135M invested in Milestone Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 12 increasing their positions, 3 reducing their positions, and 3 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 3
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
2.58% more ownership
Funds ownership: 67.77% → 70.35% (+2.6%)
2% more capital invested
Capital invested by funds: $133M → $135M (+$2.53M)
0% more funds holding
Funds holding: 28 → 28 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPC
Lion Point Capital
New York
|
+$4.27M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$2.37M |
| 3 |
Millennium Management
New York
|
+$1.89M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.12M |
| 5 |
PVI
Pura Vida Investments
New York
|
+$349K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
-$5.58M |
| 2 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$49.9K |
| 3 |
Morgan Stanley
New York
|
-$46K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$7K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PP
26
PDT Partners
New York
| $65K | +$63.5K | +10,165 | New |
|
27
BNP Paribas Financial Markets
Paris,
France
| $24.7K | +$24K | +3,848 | New |
|
28
Osaic Holdings
Scottsdale,
Arizona
| $18K | +$2.24K | +359 | +14% |
|
|
SCM
29
Suvretta Capital Management
New York
| – | -$5.58M | -851,291 | Closed |
|
|
30
UBS Group
Zurich,
Switzerland
| – | -$7K | -1,031 | Closed |
|
|
TRCT
31
Tower Research Capital (TRC)
New York
| – | -$4K | -555 | Closed |
|
MIST Hedge Fund Activity: Q1 2022 in Review
28 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Milestone Pharmaceuticals (MIST) for Q1 2022, worth a combined $135M — up 1.9% from $133M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new MIST positions and 3 closed out — a net gain of 1 holder — while 12 added to existing stakes and 3 trimmed.
The largest buyer was Lion Point Capital, opening a new position worth an estimated $4.27M. The largest seller was Suvretta Capital Management, exiting entirely with an estimated $5.58M sold.
- 28 institutional investors held Milestone Pharmaceuticals (MIST) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $135M of Milestone Pharmaceuticals stock for Q1 2022, up 1.9% quarter-over-quarter.
- 4 funds opened new Milestone Pharmaceuticals positions in Q1 2022 and 3 closed out, a net change of +1 holder.
- The largest Milestone Pharmaceuticals buyer in Q1 2022 was Lion Point Capital, an estimated $4.27M added.
- The largest Milestone Pharmaceuticals seller in Q1 2022 was Suvretta Capital Management, an estimated $5.58M sold.
Based on aggregated 13F filings for Q1 2022.